Pneumocystis jiroveci

Also found in: Dictionary, Thesaurus, Encyclopedia.

Pneu·mo·cys·tis jiroveci

the eukaryotic microorganism responsible for interstitial pneumonia in immunocompromised patients. The exact taxonomic position remains unclear, because the organism has morphologic similarities to protozoa but shares substantial 16S ribosomal RNA and mitochondrial DNA with some species of the Ascomycetes. P. jiroveci fails to grow on fungal culture media but takes up fungal stains, and infections from it respond to antiprotozoal as well as to some antifungal drugs.
See also: Pneumocystis jiroveci pneumonia.
[G. pneuma, air, breathing, + kystis, bladder, pouch]
Farlex Partner Medical Dictionary © Farlex 2012

Pneu·mo·cys·tis jir·o·ve·ci

(nū'mō-sis'tis jī-rō-vē'sī)
New nomenclature for Pneumocystis carinii, the microorganism that causes interstitial plasma cell pneumonia in immunodeficient people, particularly those with AIDS.
[G. pneuma, air, breathing, + kystis, bladder, pouch]
Medical Dictionary for the Health Professions and Nursing © Farlex 2012
Enlarge picture

Pneumocystis jiroveci

[Otto Jirovec, Czech parasitologist, 1910–1972]
An opportunistic fungus that causes lung infections in those with immunosuppressive diseases and conditions. It was formerly called pneumocystis carinii.
See: illustration
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Lindley et al., "Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: A prospective study," Thorax, vol.
One patient in this group was receiving Pneumocystis jiroveci prophylaxis and 4 patients were on HAART.
Pneumocystis jiroveci is an opportunist pathogen that causes critical and life-threatening infection in immunocompromised patients with hematologic malignancies, organ transplants, connective tissue diseases, or human immunodeficiency virus (HIV) type 1 infection.
Persistent mucocutaneous candidiasis is a common early finding, and opportunistic infections with normally nonpathogenic organisms, such as Pneumocystis jiroveci (formerly carinii) also occur.
(1) Pneumocystis carinii pneumonia (PCP) is the term commonly used for the condition, although the causative organism has been renamed Pneumocystis jiroveci [pronounced "yee-row-vet-zee"].
Sputum samples were blood-stained, but negative for acid-fast bacilli and Pneumocystis jiroveci, and only mixed oral flora were cultured.
A yeast-like fungus, Pneumocystis jiroveci, causes this form of pneumonia.
Background & objectives: Pneumocystis jiroveci (also known as P.
These include use of mesna for protection against urothelial toxicity, antifungal prophylaxis, and prophylaxis against Pneumocystis jiroveci, consideration for Staphylococcus aureus treatment, screening for cervical malignancy, counseling about infertility with CYC, screening for tuberculosis, and vaccination and assessment for osteoporosis, along with cardiovascular and thromboembolic risk assessment.
It has been renamed pneumocystis jiroveci pneumonia, although it is still known as PCP.
In the MMWR Recommendations and Reports, "Treating Opportunistic Infections Among HIV-Exposed and Infected Children: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America," in Appendix A, on page 65, an incorrect dosage was provided for infants and children with Pneumocystis jiroveci pneumonia under the column heading, "Preferred therapies and duration." The correct dosage is highlighted: "Trimethoprim-sulfamethoxazole (TMP/SMX) 15-20 mg/kg body weight TMP plus 75-100 mg/kg body weight SMX administered intravenously or by mouth in 3-4 divided doses daily (AI) (after acute pneumonitis resolved in mild-moderate disease, intravenous TMP/SMX may be changed to oral)."